Disruption of the arsenic (+3 oxidation state) methyltransferase gene in the mouse alters the phenotype for methylation of arsenic and affects distribution and retention of orally administered arsenate.
The arsenic (+3 oxidation state) methyltransferase (As3mt) gene encodes a 43 kDa protein that catalyzes methylation of inorganic arsenic. Altered expression of AS3MT in cultured human cells controls arsenic methylation phenotypes, suggesting a critical role in arsenic metabolism. Because methylated arsenicals mediate some toxic or carcinogenic effects linked to inorganic arsenic exposure, studies of the fate and effects of arsenicals in mice which cannot methylate arsenic could be instructive. This study compared retention and distribution of arsenic in As3mt knockout mice and in wild-type C57BL/6 mice in which expression of the As3mt gene is normal. Male and female mice of either genotype received an oral dose of 0.5 mg of arsenic as arsenate per kg containing [(73)As]-arsenate. Mice were radioassayed for up to 96 h after dosing; tissues were collected at 2 and 24 h after dosing. At 2 and 24 h after dosing, livers of As3mt knockouts contained a greater proportion of inorganic and monomethylated arsenic than did livers of C57BL/6 mice. A similar predominance of inorganic and monomethylated arsenic was found in the urine of As3mt knockouts. At 24 h after dosing, As3mt knockouts retained significantly higher percentages of arsenic dose in liver, kidneys, urinary bladder, lungs, heart, and carcass than did C57BL/6 mice. Whole body clearance of [(73)As] in As3mt knockouts was substantially slower than in C57BL/6 mice. At 24 h after dosing, As3mt knockouts retained about 50% and C57BL/6 mice about 6% of the dose. After 96 h, As3mt knockouts retained about 20% and C57BL/6 mice retained less than 2% of the dose. These data confirm a central role for As3mt in the metabolism of inorganic arsenic and indicate that phenotypes for arsenic retention and distribution are markedly affected by the null genotype for arsenic methylation, indicating a close linkage between the metabolism and retention of arsenicals.
Drobna
Zuzana
Z
Department of Nutrition, University of North Carolina, Chapel Hill, North Carolina 27599, USA.
Naranmandura
Hua
H
Kubachka
Kevin M
KM
Edwards
Brenda C
BC
Herbin-Davis
Karen
K
Styblo
Miroslav
M
Le
X Chris
XC
Creed
John T
JT
Maeda
Noboyu
N
Hughes
Michael F
MF
Thomas
David J
DJ
D000284:Administration, Oral; D000818:Animals; D001149:Arsenates / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000652:urine; D020261:Arsenic Poisoning; D001152:Arsenicals / Q000378:metabolism / Q000652:urine; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D008780:Methyltransferases / Q000235:genetics / Q000378:metabolism*; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D010641:Phenotype; D014018:Tissue Distribution
D001149:Arsenates; D001152:Arsenicals; D008780:Methyltransferases; C025657:arsenic acid
Toxicol Appl Pharmacol. 2008 Feb 15;227(1):26-35
18036629
Toxicol Lett. 1987 Jun;37(1):41-6
3590229
J Toxicol Environ Health A. 1998 Jan 23;53(2):95-112
9444314
Microbiol Mol Biol Rev. 2002 Jun;66(2):250-71
12040126
Toxicol Sci. 2010 Jan;113(1):70-6
19833739
Adv Enzymol Relat Subj Biochem. 1951;12:429-91
14885024
Chem Res Toxicol. 2007 Apr;20(4):616-24
17381137
Toxicol Appl Pharmacol. 2004 Aug 1;198(3):319-26
15276411
Toxicology. 2002 Jan 15;170(1-2):55-62
11750083
Toxicology. 2002 Dec 27;181-182:211-7
12505313
Toxicol Sci. 2000 Jun;55(2):460-7
10828279
Science. 2007 Jan 19;315(5810):387-9
17234949
J Nutr. 1993 Nov;123(11):1939-51
8229312
Anal Chim Acta. 2007 Jan 30;583(1):78-83
17386529
Environ Health Perspect. 2007 Jul;115(7):1081-6
17637926
Environ Health Perspect. 2003 Dec;111(16):1888-91
14644662
Chem Res Toxicol. 2005 Dec;18(12):1821-9
16359172
BMC Genomics. 2008 May 27;9:247
18505588
Toxicol Appl Pharmacol. 2003 Jan 1;186(1):7-17
12583988
Toxicol Appl Pharmacol. 2005 Sep 1;207(2):147-59
16102566
Toxicol Appl Pharmacol. 1997 Nov;147(1):101-9
9356312
Toxicology. 1999 Sep 20;137(2):95-108
10521146
Chem Biol Interact. 1985 Dec 31;56(2-3):225-38
4075449
Int J Hyg Environ Health. 2002 Oct;205(6):505-8
12455273
Toxicol Appl Pharmacol. 1995 Aug;133(2):262-8
7645022
J Toxicol Environ Health A. 1998 Jul 24;54(6):431-44
9661909
Int Arch Occup Environ Health. 1998 Feb;71(1):42-6
9523248
Toxicol Appl Pharmacol. 2006 Feb 1;210(3):171-80
15950995
Toxicol Appl Pharmacol. 2005 Apr 15;204(2):164-9
15808521
J Occup Environ Med. 2003 Mar;45(3):241-8
12661181
Toxicol Appl Pharmacol. 2009 Sep 1;239(2):137-43
19133283
Chem Biol Interact. 1984 Jun;50(1):49-57
6733804
Environ Health Perspect. 1996 Jun;104(6):620-8
8793350
Exp Biol Med (Maywood). 2007 Jan;232(1):3-13
17202581
Chem Res Toxicol. 2006 Jul;19(7):894-8
16841956
Mol Cell Biochem. 2004 Jan;255(1-2):11-8
14971641
Toxicology. 2003 Apr 15;186(1-2):33-50
12604169
Arch Toxicol. 1985 Jun;57(2):119-24
4026570